Sign in
Taking people in United StatesPhase 2

Pelacarsen for calcific aortic valve stenosis, compared with placebo

Tests pelacarsen against placebo for slowing calcific aortic valve stenosis.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Albany, Beverly Hills, Boca Raton, Boston, Bradenton, Cincinnati, Columbus, Covina, Detroit, Falls Church, Flint, Houston, Huntsville, Manassas, Miami, Miami Lakes, Minneapolis, Naples, New York, Northridge, Overland Park, Palo Alto, Philadelphia, Rochester, Royal Oak, San Diego, San Francisco, Summit, and Winston-Salem, United StatesSee the 35 sitesAlso in 14 other countries, 94 sites
Registry title
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Status
Recruiting
Phase
Phase 2
People taking part
502 people, planned
Started
7 Mar 2024
Expected to end
12 Mar 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Pelacarsen (TQJ230) 80mg
  • Matching placebo
Record updated
23 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild or moderate calcific aortic valve stenosis (a stiff, narrowed heart valve) and high Lp(a). It tests pelacarsen (TQJ230) against placebo.

Age
50 to under 80 years at screening
Sex
Men and women
Disease stage
Mild or moderate calcific aortic valve stenosis. Severe stenosis cannot join.
Earlier treatment
At randomization, existing heart and blood vessel risk factors must be fully treated.
Biomarker or test result
Lp(a) ≥175 nmol/L at screening, measured at the central laboratory

Main reasons for not taking part

  • Severe calcific aortic valve stenosis or uncontrolled high blood pressure
  • Any past cancer
  • Past bleeding stroke or other major bleeding
  • Platelet count at or below the lower normal limit
  • Active liver disease, poor liver function, significant kidney disease, or pregnant or breastfeeding

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male and female ≥50 to <80 years of age at Screening Part II
  • Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory
  • Mild or moderate calcific aortic valve stenosis
  • At the randomization visit, participant must be optimally treated for existing CV risk factors

Who cannot take part

  • Uncontrolled hypertension
  • History of malignancy of any organ system
  • History of hemorrhagic stroke or other major bleeding
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Platelet count ≤ LLN
  • Severe calcific aortic valve stenosis
  • Pregnant or nursing women; Other protocol-defined inclusion/exclusion criteria may apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 80 years old?

Where in United States

Also in 14 other countries, 94 sites

  • Capital Cardiology AssociatesAlbany, United StatesContact: Shreya ShahTaking people
  • Cardiovascular Res FoundBeverly Hills, United StatesContact: Juan RamosTaking people
  • National Heart InstituteBeverly Hills, United StatesContact: Maria FloresTaking people
  • Excel Medical Clinical Trials, LLCBoca Raton, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Brigham and Womens Hosp Harvard Med SchoolBoston, United StatesContact: Sam WongTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Victoria ViscosiTaking people
  • Tufts Medical CenterBoston, United StatesContact: Veronique RecileTaking people
  • Nova Clinical Research, LLCBradenton, United StatesContact: Sade AndrewsTaking people
  • Lindner Ctr At The Christ HospCincinnati, United StatesContact: Meghan GroneTaking people
  • Ohio State UniversityColumbus, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Flourish Clinical Resrch CovinCovina, United StatesContact: Sarita GarciaTaking people
  • Henry Ford HospitalDetroit, United StatesContact: Jodi Carter, BS, CCRPTaking people
  • Virginia HeartFalls Church, United StatesContact: Oyinda AgbaleTaking people
  • AA Medical Research CenterFlint, United StatesContact: Fayyaz ShahTaking people
  • Orion MedicalHouston, United StatesContact: Lena Olivera PerezTaking people
  • Texas Heart InstituteHouston, United StatesContact: Dominique RobertsonTaking people
  • Heart Center Research, LLCHuntsville, United StatesContact: Amy WilliamsTaking people
  • Carient Heart and VascularManassas, United StatesContact: Hameeda TasneemTaking people
  • Flourish Res Acq LLC North MiamiMiami, United StatesContact: Ashlee SealyTaking people
  • Inpatient Research Clinical LLCMiami Lakes, United StatesContact: Dora GutierrezTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Michelle PittTaking people
  • Minneapolis Heart InstituteMinneapolis, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Advanced Research for Health Improvement LLCNaples, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Icahn School of Med at Mt SinaiNew York, United StatesContact: Jay Krishna KatragaddaTaking people
  • New York - Presbyterian HospitalNew York, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Valley Clinical TrialsNorthridge, United StatesContact: Haydee GutierrezTaking people
  • Midwest Heart and Vascular SpecOverland Park, United StatesContact: Elizabeth FulksTaking people
  • Stanford University Medical CenterPalo Alto, United StatesContact: Tamara BazouziTaking people
  • Perelman School of MedicinePhiladelphia, United StatesContact: Manali ShahTaking people
  • Strong Memorial HospitalRochester, United StatesContact: Ferogh ShakouriTaking people
  • William Beaumont HospitalRoyal Oak, United StatesContact: Rachel WylieTaking people
  • University of California San DiegoSan Diego, United StatesContact: Ruby SwaimTaking people
  • UC San Francisco Medical CenterSan Francisco, United StatesContact: Liliann ZouTaking people
  • Overlook Medical CenterSummit, United StatesContact: Rosmery MontesinoTaking people
  • Wake Forest University Baptist Medical CenterWinston-Salem, United StatesContact: Donna DavisTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.

The 2 groups in the trial

  • Pelacarsen (TQJ230) 80mgTreatment being tested

    Pelacarsen (TQJ230) 80 mg prefilled syringe injected monthly, administered subcutaneously

  • Matching placeboPlacebo, for comparison

    Placebo to match pelacarsen (TQJ230) prefilled syringe injected monthly, administered subcutaneously

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
Plain-language title
Pelacarsen for calcific aortic valve stenosis, compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05646381, who can take part
Publications
Record updated
23 June 2026